Vion submits SPA to FDA for new pivotal trial of Onrigin in leukaemia
This article was originally published in Scrip
Executive Summary
Vion Pharmaceuticals has filed a special protocol assessment (SPA) with the US FDA for a new pivotal Phase II/III randomised trial of its lead oncology drug candidate Onrigin (laromustine; formerly Cloretazine) in acute myeloid leukaemia (AML).